1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

14 Sep 2024
Admin
News Article

Sobi & Enable Injections Partners to Develop and Distribute Aspaveli and enFuse Combo

Sobi, Enable Injections ink agreement to develop and distribute Aspaveli in combination with enFuse in Sobi territories

Overview

Sobi, a specialised international biopharmaceutical company, and Enable Injections, Inc. (Enable), a global healthcare innovation company, announced an international development and distribution agreement across Sobi territories for the enFuse injector, for the subcutaneous delivery of Aspaveli (pegcetacoplan).

About enFuse injector

The enFuse injector, to be produced by Enable and distributed by Sobi, is designed to streamline and improve patients’ self-administration experience with minimal disruption to their daily lives via the use of enFuse technology.
This allows wearable, hidden needle drug delivery through a simple injection under the skin.

From the CMO: Sobi

"We are dedicated to advancing innovative solutions for the treatment of rare diseases, and this agreement with Enable Injections marks an important step in fulfilling that commitment," said Lydia Abad-Franch, MD, head of R&D, medical affairs, and chief medical officer at Sobi.
“We believe the agreement with Enable will potentially expand patient choice, enhance comfort and support adherence, with the ultimate aim of better health outcomes. By continually improving the patient experience, we are working to make a meaningful difference in the lives of those we serve."

From the CEO: Enable Injections

“The future availability of Aspaveli with Enable Injections’ enFuse technology, could offer more patients the opportunity to access a simplified treatment experience that allows for greater confidence and mobility,” said Michael D. Hooven, Enable Injections' chairman and CEO.
“Enable was founded on the goal of redefining drug delivery for the benefit of patients, and our partnership with Sobi is helping us achieve that. Following regulatory approvals, enFuse will potentially be the first subcutaneous drug delivery device of its kind outside of the US and we look forward to improving the treatment experience of even more patients as we establish additional enFuse partnerships.”

Aspaveli/Empaveli Therapy

Aspaveli/Empaveli (pegcetacoplan) is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases.
It is approved for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in the United States, European Union, and other countries globally.
The therapy is also under investigation for several other rare diseases across haematology and nephrology.

Co-Development Rights

Sobi and Apellis have global co-development rights for systemic pegcetacoplan.
Sobi has exclusive ex-US commercialisation rights for systemic pegcetacoplan, and Apellis has exclusive US commercialisation rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy.

About Enable Injections

Cincinnati-based Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of enFuse.

About Sobi

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!